MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Cabaletta Bio, Inc. (Nasdaq: CABA)*
Organization & Developments: Cabaletta Bio
Parents
Cabaletta Bio, Inc. (Nasdaq: CABA)*
Children
*Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
*Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases.
*The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health.
2023: Buy Cabaletta Bio's Promising SLE Treatment_ seekingalpha.com
2023: Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology_ seekingalpha.com
2023: Cabaletta Bio: Speculative Biotech With Opportunity_seekingalpha.com
2024: Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
2024: Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities
2024: Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more
2024: CAR T for Lupus Takes Center Stage at ACR 2024
2025: Cabaletta Bio: Finding Optimism In Dire Strait
2025: Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction
2025: Cabaletta, Bristol Myers CAR-T therapies spur remissions in autoimmune disorders
Jumps
Finance & Acquisitions: Cabaletta Bio
Key People: Cabaletta Bio